Additionally, when the co-cultures were treated with MK-2206 (500 nM) in combination with Ara-C, a chemotherapy standard-of-care agent used in the treatment of leukemia, there was no significant decrease in cell viability, and, in fact, the AKT inhibitor reversed the sensitivity of the PD cells to Ara-C (Figure S1). This evidence concerns the gene AKT1 and leukemia.